NIB biotec at the Health.tech Global Summit 2026

NIB biotec will exhibit at theHealth.tech Global Summit 2026, which will take place from 3 to 5 March 2026 at Messe Basel, in the heart of the European life sciences ecosystem.
The event represents one of the most important international gatherings dedicated to healthcare innovation, bringing together startups, companies, investors, researchers, and decision makers from around the world.

A global event at the heart of European Life Sciences

The Health.tech Global Summit is recognized as a benchmark for the digital transformation of healthcare. The 2026 edition will see the participation of over 5,000 professionals, 250 exhibiting companies, and 400 investors from over 60 countries.
The summit will focus on strategic topics for the future of the sector, including prevention and personalized health, next-generation therapeutic development, modernization of care models, AI and digital health applied to patient management and diagnostic pathways.

The choice of Basel is no coincidence: the city is recognized as one of the world's leading life sciences hubs, home to companies like Roche and Novartis, and a hub for research, technology, and healthcare innovation. As the organizers stated, “Basel is the global hub for life science. And this is exactly where this summit belongs.”

A strategic platform for the most innovative companies

The event, organized as a summit+expo, will offer three days of conferences on four thematic stages, workshops, masterclasses and live demos, startup competitions and spaces dedicated to networking.

NIB Biotec will have its own booth in the exhibition area dedicated to innovative biotech, medtech, and healthtech companies. This will allow us to showcase our diagnostic solutions based on urinary biomarkers and engage with strategic clinical and industrial partners and investors.

An opportunity to tell our innovation

Participation in the summit represents an important step in our growth journey. Following NIB biotec's recent achievements, including the development of urinary biomarkers in prostate cancer and its presence at scientific and international events, Basel 2026 will be a key opportunity to showcase the results of our work and the potential of our technology.

We look forward to meeting with researchers, clinicians, investors, and partners to share our vision and discuss how our diagnostic tests can be integrated into next-generation cancer prevention and surveillance pathways.

We look forward to seeing you in Basel!